BACKGROUND: Abnormalities in mineral metabolism are common complications of organ transplantation. The role of immunosuppressive agents in alteration of mineral metabolism is not clear. METHODS: We conducted an animal study to investigate the effects of cyclosporine A (CsA), tacrolimus, and sirolimus on renal calcium, magnesium and vitamin D metabolism. RESULTS: CsA and tacrolimus induced a 2- to 3-fold and 1.6- to 1.8-fold increase in urinary calcium and magnesium excretion, respectively, while rapamycin had no effects on calcium, but doubled the urinary magnesium excretion. CsA and tacrolimus, but not rapamycin, elevated serum 1,25(OH)(2) vitamin D without affecting the parathyroid hormone level. CsA and tacrolimus reduced mRNA abundance in TRPV5 (CsA: 64 ± 3% of control; tacrolimus: 50 ± 3%) calbindin-D28k (CsA: 62 ± 4%; tacrolimus: 43 ± 3%), and vitamin D receptor (CsA: 52 ± 3%; tacrolimus: 58 ± 2%, all p < 0.05). Rapamycin did not affect gene expression in any of studied proteins. The immunofluorescence staining study demonstrated a 50% reduction of TRPV5 and calbindin-D28k by CsA and tacrolimus. CONCLUSION: The suppression of VDR by calcineurin inhibitors is probably the underlying mechanism of renal calcium wasting. In spite of an increased 1,25(OH)(2) vitamin D level, the kidney is not able to reserve calcium, suggesting a role of vitamin D resistance that may be related to bone loss.
BACKGROUND: Abnormalities in mineral metabolism are common complications of organ transplantation. The role of immunosuppressive agents in alteration of mineral metabolism is not clear. METHODS: We conducted an animal study to investigate the effects of cyclosporine A (CsA), tacrolimus, and sirolimus on renal calcium, magnesium and vitamin D metabolism. RESULTS:CsA and tacrolimus induced a 2- to 3-fold and 1.6- to 1.8-fold increase in urinary calcium and magnesium excretion, respectively, while rapamycin had no effects on calcium, but doubled the urinary magnesium excretion. CsA and tacrolimus, but not rapamycin, elevated serum 1,25(OH)(2) vitamin D without affecting the parathyroid hormone level. CsA and tacrolimus reduced mRNA abundance in TRPV5 (CsA: 64 ± 3% of control; tacrolimus: 50 ± 3%) calbindin-D28k (CsA: 62 ± 4%; tacrolimus: 43 ± 3%), and vitamin D receptor (CsA: 52 ± 3%; tacrolimus: 58 ± 2%, all p < 0.05). Rapamycin did not affect gene expression in any of studied proteins. The immunofluorescence staining study demonstrated a 50% reduction of TRPV5 and calbindin-D28k by CsA and tacrolimus. CONCLUSION: The suppression of VDR by calcineurin inhibitors is probably the underlying mechanism of renal calcium wasting. In spite of an increased 1,25(OH)(2) vitamin D level, the kidney is not able to reserve calcium, suggesting a role of vitamin D resistance that may be related to bone loss.
Authors: Marie-Claude Monier-Faugere; Hanna Mawad; Quanle Qi; Robert M Friedler; Hartmut H Malluche Journal: J Am Soc Nephrol Date: 2000-06 Impact factor: 10.121
Authors: A Blanchard; X Jeunemaitre; P Coudol; M Dechaux; M Froissart; A May; R Demontis; A Fournier; M Paillard; P Houillier Journal: Kidney Int Date: 2001-06 Impact factor: 10.612
Authors: D F Romero; F J Buchinsky; B Rucinski; M Cvetkovic; H P Bryer; X G Liang; Y F Ma; W S Jee; S Epstein Journal: J Bone Miner Res Date: 1995-05 Impact factor: 6.741
Authors: Gerardo Sarno; Giuseppe Daniele; Giacomo Tirabassi; Alberto O Chavez; Opeolu O Ojo; Francesco Orio; Hana Kahleova; Giancarlo Balercia; William B Grant; Paride De Rosa; Annamaria Colao; Giovanna Muscogiuri Journal: Endocrine Date: 2015-05-22 Impact factor: 3.633
Authors: Agnieszka Prytuła; Johan Vande Walle; Hans Van Vlierberghe; Jean-Marc Kaufman; Tom Fiers; Jo Dehoorne; Ann Raes Journal: Endocrine Date: 2015-10-03 Impact factor: 3.633
Authors: Luigi Francesco Morrone; Pergiorgio Bolasco; Corrado Camerini; Giuseppe Cianciolo; Adamasco Cupisti; Andrea Galassi; Sandro Mazzaferro; Domenico Russo; Luigi Russo; Mario Cozzolino Journal: J Nephrol Date: 2016-04-09 Impact factor: 3.902